HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online-Only Appendix All Versions of this Article: dc06-2440v1 30/8/2080    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gach, A. Articles by Mlynarski, W. Search for Related Content PubMed PubMed Citation Articles by Gach, A. Articles by Mlynarski, W. Social Bookmarking                What's this?

Islet-Specific Antibody Seroconversion in Patients With Long Duration of Permanent Neonatal Diabetes Caused by Mutations in the KCNJ11 Gene

¹ Department of Pediatrics, Medical University of Lodz, Lodz, Poland
² Department of Metabolic Diseases, Jagiellonian University, Krakow, Poland
³ Department of Endocrinology and Diabetology for Children and Adolescents, Medical University, Wroclaw, Poland
⁴ Department of Pediatric Endocrinology, Polish-American Children Hospital, Krakow, Poland
⁵ Diabetes Outpatient Clinic, Children's Hospital, Kielce, Poland

Address correspondence and reprint requests to Wojciech Mlynarski, MD, PhD, Department of Pediatrics, Medical University of Lodz, 38/50 Sporna St., 91-738 Lodz, Poland. E-mail: wojciech.mlynarski@joslin.harvard.edu

Abbreviations: PNDM, permanent neonatal diabetes

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
Heterozygous activating mutations in the KCNJ11 gene are a common cause of permanent neonatal diabetes (PNDM) (1,2). In contrast to the autoimmune type 1 diabetes, patients with KCNJ11 mutations do not have serological markers of autoimmune ß-cell destruction at disease onset (1,3–5). In such patients, hyperglycemia does not result from insulin-secreting cell destruction but rather from impaired insulin secretion. In addition, the majority of cases can be corrected with sulfonylurea therapy (2,6). Here, we report that carriers of the KCNJ11 mutation that are immunonegative at onset may show presence of islet antibodies in the further course of the disease.

	RESEARCH DESIGN AND METHODS—

 
We sought to evaluate the clinical and genetic characteristics of patients with neonatal diabetes in Poland, using the Nationwide Registry, which was established in 2005 (7,8). Automatic sequencing of the KCNJ11 gene allowed identification of 15 patients with heterozygous mutations that cause neonatal diabetes. Sera from 11 carriers of the KCNJ11 gene mutation were available for the present study. None of the patients had a family history of type 1 diabetes. Informed consent was obtained from all subjects or their parents. The study was conducted in accordance with the Declaration of Helsinki (revised in 2000) and . . . [Full Text of this Article]

ß-Cell antibody analysis
At diabetes onset.
At study entry.

	RESULTS—

 

	CONCLUSIONS—

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Aguilar-Bryan and J. Bryan Neonatal Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 265 - 291. [Abstract] [Full Text] [PDF]